This brand name is authorized in South Africa
The drug RETAANE contains one active pharmaceutical ingredient (API):
|
1
Anecortave
UNII Y0PC411K4T - ANECORTAVE ACETATE
|
|
Anecortave, a synthetic cortisone, has been shown to have antiangiogenic properties that have been established in multiple experimental models of angiogenesis. Anecortave is under investigation to treat exudative age-related macular degeneration (AMD). Although similar in chemical structure to the corticosteroid hydrocortisone acetate, it possesses no glucocorticoid activity. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| S01LA02 | Anecortave | S Sensory organs → S01 Ophthalmologicals → S01L Ocular vascular disorder agents → S01LA Antineovascularisation agents |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: ZA | Health Products Regulatory Authority | Identifier(s): A40/15.4/0009 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
